Blood Vesicle Proteins and Lipids Reveal Early Parkinson's Disease Signatures Across Age Groups

Parkinson's disease is the fastest-growing neurodegenerative disorder, yet it is usually diagnosed late and has no reliable blood test. Alpha-synuclein assays work in cerebrospinal fluid but are unstable in blood, and PD is often clinically confused with multiple system atrophy (MSA). Extracellular vesicles (EVs) can cross the blood-brain barrier and carry both proteins and lipids, making them an attractive source of biomarkers that could also show how the two molecule types interact in disease.

The team used an in-house affinity-based, magnetic-bead EV isolation method on small plasma volumes. Isolated vesicles showed typical morphology, a size of about 60–70 nm, and canonical markers (CD9, TSG101, HSP70) without calnexin. The discovery cohort had 131 participants: 40 PD patients, 31 aged controls, and 60 young controls. The validation cohort had 63 people (33 PD, 15 aged controls, 15 young controls). Separate groups included 19 prodromal PD cases, 10 MSA cases, and 5 PD patients with paired plasma and CSF. Mass spectrometry quantified 3,795 EV proteins and 2,236 EV lipids. Candidates were then checked by targeted parallel reaction monitoring (PRM), co-expression network analysis (WGCNA), and machine learning.

By requiring differences in PD versus both control groups, the authors defined 179 age-independent differentially expressed EV proteins (114 up, 65 down) and 136 age-independent lipids (45 up, 91 down). Up-regulated proteins clustered into lipoprotein metabolism (APOE, APOD, APCS, LIPC), complement, coagulation, and acute inflammation. Down-regulated proteins included hemoglobin subunits and PDGF family members. Up-regulated lipids were mostly triglycerides and diglycerides, while down-regulated lipids were largely phospholipids such as PS, PE, and PC. APOE, APOH, and APOD correlated with many lipids, suggesting lipid-mediated modulation of APOE signaling. Seven proteins (e.g., SEMA3C, VNN2, PTPN23, STX4, CCT8) and 37 lipids were age-dependent. They fell in older controls versus young and rose again in PD. Some protein modules tracked clinical measures such as Hoehn-Yahr stage and non-motor symptom scores. Comparison with MSA yielded 126 PD-specific proteins and 102 PD-specific lipids. Of 126 PD-specific proteins, 27 were detectable in both plasma and CSF EVs with concordant regulation. PRM confirmed upregulation of APOE, KNG1, KLKB1, APCS, APOD, CFH, and GC, and downregulation of hemoglobin proteins; APOE was the most consistent candidate.

These findings suggest EV protein-lipid signatures could support early detection, risk stratification, and PD-versus-MSA discrimination, and they point to lipid and APOE pathways as possible intervention targets. Important caveats: the cohorts are modest, particularly the prodromal (n=19), MSA (n=10), and CSF (n=5) groups, and the age-dependent findings come from cross-sectional comparisons. Some inflammation, coagulation, and hemoglobin signals may reflect plasma contamination or peripheral processes rather than brain-derived EVs. The provided text was truncated before the prodromal, machine learning, and mediation results, so those are not detailed here. Independent multi-center, longitudinal validation is needed.